undamentalytics Newsletter
Sign in

Castle Biosciences Inc income statement

In fiscal 2025, Castle Biosciences Inc reported revenue of $344m, up 3.7% on the year before, operating income of −$42.8m (a -12.4% margin) and net income of −$24.2m, or −$0.83 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue23526394137220332344357
Cost of revenue5710163245607181
Gross profit17455378105175272273276
Research and development5713304554525255
Selling, general and administrative16304887143180200229244
Operating income−47−7−40−73−689−43−32
Interest expense253000100
Income tax000−9−203−50
Net income−65−10−31−67−5718−24−19
Diluted EPS−$5.33−$0.21−$0.54−$1.24−$2.58−$2.14$0.62−$0.83−$0.66
Diluted shares (average)2m9m19m25m26m27m29m29m30m
EBITDA−48−6−37−62−5625−2−21

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CSTL vs FLGTCSTL vs TWSTCSTL vs SDGR

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Castle Biosciences Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Castle Biosciences Inc.